STOCKHOLM, Sweden, Feb. 13, 2003 (PRIMEZONE) -- Biora AB (publ) (Other OTC:BIORY)
4th Qtr 4th Qtr Full Year Full Year
2002 2001 2002 2001
Net sales, SEK million 30.2 32.9 129.7 110.7
Operating result, SEK million 0.5 0.2 -0.9 -26.5
Net result, SEK million 1.2 0.6 0.7 -25.1
- Net result for 2002 was a profit of SEK 0.7 million (compared to a net loss of SEK 25.1 million for 2001).
- Sales during 2002 increased by 17 percent to SEK 129.7 million (compared to SEK 110.7 million for 2001).
- Sales during the fourth quarter of 2002 amounted to SEK 30.2 million (compared to SEK 32.9 million for the fourth quarter of 2001).
- Significant negative impact on sales for 2002 due to a decline in the U.S. dollar exchange rate.
- Net change in cash for 2002 was SEK - 0.1 million (compared to SEK - 2.3 million for 2001).
Biora develops, manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain(R)Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates the tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/02/13/20030213BIT00620/wkr0001.doc
http://www.waymaker.net/bitonline/2003/02/13/20030213BIT00620/wkr0002.PDF